低剂量米尔德罗纳酸衍生脂类物质用于有效的mRNA疫苗配送,具有最小的炎症副作用
Jiwei Liu1, Bing Xiao2, Yongle Yang3
1Zhejiang Key Laboratory of Smart Biomaterials, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China.
ACS nano
|August 16, 2024
概括
来自米尔德罗纳特的新脂类纳米粒子 (LNPs) 显示对mRNA疫苗的炎症减少. 这些新的mLNP-69系统有效地提供mRNA癌症疫苗,在临床前模型中防止瘤生长.
科学领域:
- 生物技术是生物技术.
- 疫苗学 疫苗学 疫苗学
- 纳米医学是一种纳米医学.
背景情况:
- 使者RNA (mRNA) 疫苗为疾病预防和治疗提供了革命性的潜力.
- 炎症性副作用,通常与脂质纳米粒子 (LNP) 输送系统有关,限制了mRNA技术的更广泛应用.
研究的目的:
- 为mRNA疫苗开发一种具有减少炎症潜力的新型LNP输送系统.
- 评估一种新型的LNP配方 (mLNP-69) 的疗效和安全性,该配方是从基于米德罗纳特的皮质脂 (mLPs) 中衍生而来的.
主要方法:
- 从米尔多酸盐中制备阴性脂质 (mLPs) 并将其配制成mLNP-69.
- 使用SM-102.2对mLNP-69与标准LNP (sLNP) 的比较分析.
- 在临床前B16-OVA黑色素瘤模型中mRNA输送和抗瘤功效的体内评估.
主要成果:
- 与sLNP相比,mLNP-69证明了有效的mRNA传递,并显著减少了局部炎症.
- 在临床前模型中,mLNP-69促进了mRNA癌症疫苗的成功输送,防止瘤发生和阻碍瘤进展.
- 来自米尔德罗纳特的酸性脂质显示出高效的输送能力和最小的炎症副作用.
结论:
- 来自米尔德罗纳酸的阴性脂质为开发更安全,更有效的mRNA输送系统提供了一个有前途的平台.
- mLNP-69代表了LNP技术的重大进步,有可能克服当前mRNA疫苗的关键局限性.
- 这些发现表明,mLNP-69对于基于mRNA的疗法和疫苗的临床转化具有很大的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
604
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
604
MicroRNAs
21.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K


